Icosavax Inc ICVX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 08/12/22 EDT
8.98UNCH (UNCH)
Volume
1,568
Close
8.98quote price arrow up+0.57 (+6.78%)
Volume
87,371
52 week range
4.00 - 41.98
Loading...
  • Open9.03
  • Day High9.48
  • Day Low8.18
  • Prev Close8.41
  • 52 Week High41.98
  • 52 Week High Date09/16/21
  • 52 Week Low4.00
  • 52 Week Low Date03/28/22

Key Stats

  • Market Cap356.78M
  • Shares Out39.73M
  • 10 Day Average Volume0.08M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-60.75

KEY STATS

  • Open9.03
  • Day High9.48
  • Day Low8.18
  • Prev Close8.41
  • 52 Week High41.98
  • 52 Week High Date09/16/21
  • 52 Week Low4.00
  • 52 Week Low Date03/28/22
  • Market Cap356.78M
  • Shares Out39.73M
  • 10 Day Average Volume0.08M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-60.75

RATIOS/PROFITABILITY

  • EPS (TTM)-2.16
  • P/E (TTM)-4.16
  • Fwd P/E (NTM)-3.92
  • EBITDA (TTM)-84.747M
  • ROE (TTM)-74.47%
  • Revenue (TTM)6.38M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,326.23%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date09/13/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Icosavax Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Icosavax, Inc. is a biopharmaceutical company. The Company uses its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on respiratory diseases. Its VLP platform technology is designed to enable the multivalent, particle-based display of complex viral antigens. The Company's pipeline includes vaccine candidates targeting viral causes of pneumonia. Its vaccine candidate IVX-A12 is a bivalent candidate or a mixture of two...
Mark McDade
Independent Chairman of the Board
Adam Simpson
President, Chief Executive Officer, Director
Thomas Russo
Chief Financial Officer
Elizabeth Bekiroglu
General Counsel, Corporate Secretary
Address
1616 EASTLAKE AVE E, SUITE 208
Seattle, WA
98102
United States

Top Peers

SYMBOLLASTCHG%CHG
ABSI
Absci Corp
4.78-0.01-0.21%
TRDA
Entrada Therapeutics Inc
12.63-0.07-0.55%
KALV
Kalvista Pharmaceuticals Inc
14.82+1.06+7.70%
BMEA
Biomea Fusion Inc
11.94+0.44+3.78%
FULC
Fulcrum Therapeutics Inc
8.41+0.84+11.10%